Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

BACKGROUND: The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in CA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Handlos Grauslund, Jacob, Holmström, Morten Orebo, Jørgensen, Nicolai Grønne, Klausen, Uffe, Weis-Banke, Stine Emilie, El Fassi, Daniel, Schöllkopf, Claudia, Clausen, Mette Borg, Gjerdrum, Lise Mette Rahbek, Breinholt, Marie Fredslund, Kjeldsen, Julie Westerlin, Hansen, Morten, Koschmieder, Steffen, Chatain, Nicolas, Novotny, Guy Wayne, Petersen, Jesper, Kjær, Lasse, Skov, Vibe, Met, Özcan, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952976/
https://ncbi.nlm.nih.gov/pubmed/33718228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.637420
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados